--- title: "Inside Wall Street's Fringes: CXApp's Survival Bid and Summit's Data Scrutiny" type: "News" locale: "en" url: "https://longbridge.com/en/news/296337679.md" description: "Capital is quietly shifting toward the market's fringes. I'm told CXApp is banking on AI and a reverse split to survive, while Summit's cancer drug faces renewed data scrutiny despite recent approvals." datetime: "2026-08-19T10:12:23.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296337679.md) - [en](https://longbridge.com/en/news/296337679.md) - [zh-HK](https://longbridge.com/zh-HK/news/296337679.md) generator: "portal-rs" --- # Inside Wall Street's Fringes: CXApp's Survival Bid and Summit's Data Scrutiny The market isn't just a playground for mega-caps. This week, I've noticed capital drifting into the market's fringes—highly specialized micro-caps and niche financial vehicles. According to people familiar with the matter, these assets are undergoing their most significant overhaul since 2024, from AI workplace startups fighting for survival to a quiet boom in private credit. ### CXApp (CXAI.US) CXApp has been teetering on the edge of delisting, but a recent 1-for-50 reverse stock split has temporarily saved its spot on the Nasdaq, amidst wild fluctuations this year. I'm told the management's main trump card is a new enterprise agentic layer called CXAI 2.0. With the recent acquisition of EngineRoom, the company expects to push its annual recurring revenue (ARR) above **USD 12M**. This could be the company's most critical test before the next earnings. ### Summit Therapeutics (SMMT.US) Even though its lead candidate Ivonescimab secured a third indication approval in China in August 2026, Summit's stock still saw a notable pullback recently. According to people familiar with the matter, Wall Street is concerned about updated data showing the progression-free survival (PFS) risk reduction shrinking from 40% to 28%, which could complicate the drug's path to approval in Western markets. ### Blackstone Secured Lending Fund (BXSL.US) This Blackstone BDC is a quiet winner in the private credit boom, charting a steady course recently. Its portfolio's fair value reached **USD 13.1B** by late 2024, and Moody's recently upgraded its rating to Baa2. I'm told its **11.5%** annualized dividend yield is attracting a wave of institutional money seeking safe-haven returns. ### Avantor (AVTR.US) As a key supplier to the biopharma industry, Avantor's recovery has been somewhat sluggish, with its stock underperforming the broader market. Net sales for Q2 dropped 2.4% year-over-year to **USD 1.7B**. However, individuals close to the company indicate that the decline in its biosciences product segment has narrowed to 0.5%, and management is planning a new round of cost optimizations later this year. ### RadNet (RDDC.US) RadNet's network of outpatient imaging centers is accelerating its integration with AI. Total revenue hit a record **USD 459.7M** in Q2 2024, while its digital health segment surged 36.4%. I'm told its DeepHealth subsidiary just completed the acquisition of iCAD and is integrating ultrasound workflows with Siemens Healthineers, marking the most significant AI deployment in this sub-sector. ### Also - **Moleculin Biotech (MBRX.US)**: Its AML drug Annamycin is advancing in Phase III trials, with recent interim data showing a 62% complete remission rate. Definitely one to watch later this year. - **PIMCO Corporate & Income Opportunity Fund (PTY.US)**: Maintaining a TTM dividend yield over 12%, this closed-end fund saw a massive jump in net income recently, cementing its status as a defensive high-yield play. - **Franklin FTSE South Korea ETF (FLKR.US)**: Heavily weighted toward Samsung and SK Hynix, this ETF has faced headwinds recently amid tech volatility. I'm told external investors are actively reassessing the Korean semiconductor supply chain. - **Vonage (VG.US)**: With limited independent news since its acquisition by Ericsson, people familiar with the matter say the parent company is accelerating the integration of Vonage's APIs into its core network services. - **Direxion Daily Gold Miners Index Bear 2X Shares (DUST.US)**: Extreme volatility in the gold mining sector recently has turned this 2x leveraged inverse ETF into a highly active trading vehicle for hedging funds. *This article does not constitute investment advice.* ### Related Stocks - [CXAI.US](https://longbridge.com/en/quote/CXAI.US.md) - [SMMT.US](https://longbridge.com/en/quote/SMMT.US.md) - [AVTR.US](https://longbridge.com/en/quote/AVTR.US.md) - [MBRX.US](https://longbridge.com/en/quote/MBRX.US.md) - [VG.US](https://longbridge.com/en/quote/VG.US.md) ## Related News & Research - [Advisors Capital Management LLC Invests $4.37 Million in Avantor, Inc. $AVTR](https://longbridge.com/en/news/296674919.md) - [Moleculin Biotech announces annual shareholder meeting](https://longbridge.com/en/news/296828733.md) - [Vise Technologies Inc. Takes $731,000 Position in Avantor, Inc. $AVTR](https://longbridge.com/en/news/296763261.md) - [Venture Global Senior VP Development Fory Musser disposes of USD 3.87 million in common shares](https://longbridge.com/en/news/296536987.md) - [Venture Global Senior VP Fory Musser disposes of 469,547 common shares for $6.58 million](https://longbridge.com/en/news/296269732.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**